vs
Side-by-side financial comparison of PROG Holdings, Inc. (PRG) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $651.6M, roughly 1.1× PROG Holdings, Inc.). PROG Holdings, Inc. runs the higher net margin — 5.5% vs -104.7%, a 110.3% gap on every dollar of revenue. On growth, PROG Holdings, Inc. posted the faster year-over-year revenue change (457.1% vs -3.7%). Over the past eight quarters, PROG Holdings, Inc.'s revenue compounded faster (4.9% CAGR vs -2.9%).
PROG Holdings, Inc. is a U.S.-based financial technology firm providing flexible lease-to-own and point-of-sale financing solutions to consumers. Operating primarily in the U.S. market, its core segments include retail partner financing, consumer lending, and payment services that help customers access electronics and household goods without traditional credit requirements.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
PRG vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $651.6M | $699.9M |
| Net Profit | $36.1M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | 10.0% | -100.7% |
| Net Margin | 5.5% | -104.7% |
| Revenue YoY | 457.1% | -3.7% |
| Net Profit YoY | 3.8% | -3583.4% |
| EPS (diluted) | $3.68 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $651.6M | — | ||
| Q4 25 | $525.4M | — | ||
| Q3 25 | $595.1M | $699.9M | ||
| Q2 25 | $604.7M | $613.9M | ||
| Q1 25 | $684.1M | $692.8M | ||
| Q4 24 | $558.9M | $707.8M | ||
| Q3 24 | $606.1M | $727.1M | ||
| Q2 24 | $592.2M | $637.0M |
| Q1 26 | $36.1M | — | ||
| Q4 25 | $40.5M | — | ||
| Q3 25 | $33.1M | $-733.0M | ||
| Q2 25 | $38.5M | $-255.4M | ||
| Q1 25 | $34.7M | $-12.7M | ||
| Q4 24 | $57.5M | $-178.4M | ||
| Q3 24 | $84.0M | $-19.9M | ||
| Q2 24 | $33.8M | $-147.7M |
| Q1 26 | 10.0% | — | ||
| Q4 25 | 6.9% | — | ||
| Q3 25 | 9.0% | -100.7% | ||
| Q2 25 | 10.0% | -29.4% | ||
| Q1 25 | 8.2% | 4.7% | ||
| Q4 24 | 8.9% | -14.2% | ||
| Q3 24 | 8.1% | 2.1% | ||
| Q2 24 | 9.4% | -18.4% |
| Q1 26 | 5.5% | — | ||
| Q4 25 | 7.7% | — | ||
| Q3 25 | 5.6% | -104.7% | ||
| Q2 25 | 6.4% | -41.6% | ||
| Q1 25 | 5.1% | -1.8% | ||
| Q4 24 | 10.3% | -25.2% | ||
| Q3 24 | 13.9% | -2.7% | ||
| Q2 24 | 5.7% | -23.2% |
| Q1 26 | $3.68 | — | ||
| Q4 25 | $0.99 | — | ||
| Q3 25 | $0.82 | $-10.78 | ||
| Q2 25 | $0.95 | $-3.77 | ||
| Q1 25 | $0.83 | $-0.19 | ||
| Q4 24 | $1.33 | $-2.54 | ||
| Q3 24 | $1.94 | $-0.30 | ||
| Q2 24 | $0.77 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $69.4M | $98.1M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $774.4M | $2.0B |
| Total Assets | $2.0B | $5.7B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $69.4M | — | ||
| Q4 25 | $308.8M | — | ||
| Q3 25 | $292.6M | $98.1M | ||
| Q2 25 | $222.0M | $151.7M | ||
| Q1 25 | $213.3M | $127.1M | ||
| Q4 24 | $90.9M | $98.3M | ||
| Q3 24 | $221.7M | $143.7M | ||
| Q2 24 | $250.1M | $107.0M |
| Q1 26 | — | — | ||
| Q4 25 | $594.9M | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | $643.6M | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | $774.4M | — | ||
| Q4 25 | $746.4M | — | ||
| Q3 25 | $703.6M | $2.0B | ||
| Q2 25 | $668.7M | $2.8B | ||
| Q1 25 | $654.4M | $3.0B | ||
| Q4 24 | $650.3M | $3.0B | ||
| Q3 24 | $630.8M | $3.2B | ||
| Q2 24 | $581.9M | $3.2B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | $5.7B | ||
| Q2 25 | $1.5B | $6.4B | ||
| Q1 25 | $1.5B | $6.5B | ||
| Q4 24 | $1.5B | $6.4B | ||
| Q3 24 | $1.4B | $6.8B | ||
| Q2 24 | $1.5B | $6.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | 0.99× | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-54.9M | — | ||
| Q3 25 | $110.0M | $-45.5M | ||
| Q2 25 | $69.9M | $-46.8M | ||
| Q1 25 | $209.9M | $65.6M | ||
| Q4 24 | $-84.5M | $63.7M | ||
| Q3 24 | $31.9M | $117.9M | ||
| Q2 24 | $55.4M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-57.5M | — | ||
| Q3 25 | $106.5M | $-94.7M | ||
| Q2 25 | $68.0M | $-84.3M | ||
| Q1 25 | $208.0M | $9.4M | ||
| Q4 24 | $-86.8M | $16.5M | ||
| Q3 24 | $29.8M | $71.4M | ||
| Q2 24 | $53.5M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | -10.9% | — | ||
| Q3 25 | 17.9% | -13.5% | ||
| Q2 25 | 11.2% | -13.7% | ||
| Q1 25 | 30.4% | 1.4% | ||
| Q4 24 | -15.5% | 2.3% | ||
| Q3 24 | 4.9% | 9.8% | ||
| Q2 24 | 9.0% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.6% | 7.0% | ||
| Q2 25 | 0.3% | 6.1% | ||
| Q1 25 | 0.3% | 8.1% | ||
| Q4 24 | 0.4% | 6.7% | ||
| Q3 24 | 0.3% | 6.4% | ||
| Q2 24 | 0.3% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | -1.36× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 1.82× | — | ||
| Q1 25 | 6.05× | — | ||
| Q4 24 | -1.47× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRG
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
